The Numbers Are In

I n this issue of Circulation, Mora et al demonstrate for the first time that statins are effective for the primary prevention of cardiovascular events in women. 1 Under a prespecified analysis, the authors examined sex-specific outcomes in JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), which enrolled 6801 women Ն60 years old and 11 001 men Ն50 years old without prior history of coronary heart disease, diabetes mellitus, or stroke who had low-density lipoprotein cholesterol (LDL-C) Ͻ130 mg/dL and high-sensitivity C-reactive protein (hsCRP) Ն2.0 mg/L.